Nikita Shah Sells 146,403 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Nikita Shah sold 146,403 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the sale, the executive vice president directly owned 253,390 shares of the company’s stock, valued at approximately $4,436,858.90. The trade was a 36.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $18.15 on Friday. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $9.20 and a fifty-two week high of $19.26. The stock’s 50-day moving average is $17.24 and its two-hundred day moving average is $14.59. The firm has a market cap of $5.80 billion, a P/E ratio of 37.04 and a beta of 1.27.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in AMRX. Kemnay Advisory Services Inc. acquired a new position in Amneal Pharmaceuticals during the fourth quarter valued at approximately $26,000. Federated Hermes Inc. lifted its stake in shares of Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after buying an additional 2,168 shares during the last quarter. Comerica Bank lifted its stake in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares during the last quarter. Transamerica Financial Advisors LLC boosted its holdings in shares of Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after buying an additional 2,460 shares during the period. Finally, Focus Partners Wealth bought a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth $42,000. Institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on AMRX. Zacks Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, August 7th. The Goldman Sachs Group reissued a “buy” rating and issued a $21.00 target price on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday. Finally, Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $17.67.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.